Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade by Hathaway, Catherine K. et al.
Endothelin-1 critically influences cardiac function via
superoxide-MMP9 cascade
Catherine K. Hathawaya, Ruriko Granta, John R. Hagamana, Sylvia Hillera, Feng Lia, Longquan Xua, Albert S. Changa,
Victoria J. Maddena, C. Robert Bagnella, Mauricio Rojasb, Hyung-Suk Kima, Bingruo Wuc, Bin Zhouc, Oliver Smithiesa,1,
and Masao Kakokia,1
aDepartment of Pathology and Laboratory Medicine and bDepartment of Medicine, University of North Carolina, Chapel Hill, NC 27599; and cDepartment of
Genetics, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461
Contributed by Oliver Smithies, March 10, 2015 (sent for review January 5, 2015)
We have generated low-expressing and high-expressing endothelin-1
genes (L and H) and have bred mice with four levels of expression:
L/L, ∼20%; L/+, ∼65%; +/+ (wild type), 100%; and H/+, ∼350%.
The hypomorphic L allele can be spatiotemporally switched
to the hypermorphic H allele by Cre-loxP recombination. Young
adult L/L and L/+ mice have dilated cardiomyopathy, hypertension,
and increased plasma volumes, together with increased ventricular
superoxide levels, increased matrix metalloproteinase 9 (Mmp9)
expression, and reduced ventricular stiffness. H/+ mice have de-
creased plasma volumes and significantly heavy stiff hearts.
Global or cardiomyocyte-specific switching expression from L to
H normalized the abnormalities already present in young adult
L/L mice. An epithelial sodium channel antagonist normalized
plasma volume and blood pressure, but only partially corrected
the cardiomyopathy. A superoxide dismutase mimetic made super-
oxide levels subnormal, reducedMmp9 overexpression, and substan-
tially improved cardiac function. Genetic absence of Mmp9 also
improved cardiac function, but increased superoxide remained. We
conclude that endothelin-1 is critical for maintaining normal contrac-
tile function, for controlling superoxide and Mmp9 levels, and for
ensuring that the myocardium has sufficient collagen to prevent
overstretching. Even amodest (∼35%) decrease in endothelin-1 gene
(Edn1) expression is sufficient to cause cardiac dysfunction.
amiloride | extracellular matrix | reactive oxygen species | sodium
retention | tempol
Previous studies have demonstrated that individuals withdilated cardiomyopathy have increased plasma levels of
endothelin-1 (1) and elevated endothelin-1 mRNA levels in the
heart (2). In addition, two polymorphisms in the endothelin type
A receptor gene (EDNRA), G231A and C1363T, are associated
with differences in the risk for pathogenesis and mortality in
patients with idiopathic dilated cardiomyopathy (3, 4). These
findings suggest endothelin-1 plays a causative and/or compen-
satory role in dilated cardiomyopathy.
In animal studies, mice completely lacking endothelin-1 have
severe anomalies in the heart and aorta with craniofacial ab-
normalities and die at age 10–12 d post coitum (5). Mice with a
cardiomyocyte-specific deletion of endothelin-1 develop dilated
cardiomyopathy as they age or if they are subjected to aortic
banding when young (6). In the opposite direction, mice having a
conditional ∼10-fold overexpression of endothelin-1 in the heart
also develop dilated cardiomyopathy associated with increases in
the expression of inflammatory cytokines (7).
To gain a better understanding of the physiological role of
endothelin-1 in mammals, we have used a method of altering the
3′ untranslated region (UTR) of a gene of interest without
changing its 5′ transcriptional regulatory elements (8) to gener-
ate mice having four step-wise levels of expression of endothelin-1
covering physiologically likely ranges (from ∼20% normal to
∼350%). We here report that plasma volumes and blood pres-
sure increase progressively as the expression of endothelin-1
gene (Edn1) decreases, and that decreasing expression of Edn1
by as little as 35% causes severely dilated cardiomyopathy. A
threefold increase in expression of endothelin-1 causes slight
cardiac hypertrophy. Using tissue-specific switching of Edn1 ex-
pression from low to high, we show that increases in superoxide
levels and expression of matrix metalloproteinase 9 (Mmp9) play
important roles in the cardiac dysfunction of the endothelin-1
hypomorphs. Together, our results show that cardiac function is
sensitive to even modest decreases in endothelin-1 levels.
Generation of Hypo/Hypermorphic Mice for Endothelin-1
As a first step in generating modified forms of the Edn1 gene
expressing low or high levels of endothelin-1 for use in studies of
the effects of both loss of function and gain of function of
endothelin-1, we first compared the relative effects on mRNA
stability of the 3′ UTR of WT gene (Edn1) with a panel of other
3′ UTRs, as described previously (9) (SI Appendix, Fig. S1). This
comparison showed that the 3′ UTR of Edn1 reduces mRNA
stability to the same extent as that caused by the 3′UTR of the
Fos gene, which has one of the most short-lived mRNAs we have
studied (SI Appendix, Figs. S2 and S3). This result indicates that
the levels of Edn1 mRNA can change rapidly in response to
decreases or increases in demand, as previously described (10).
To generate a form of the Edn1 gene (L) with lower-than-
normal expression, we used gene targeting in mouse embryonic
stem cells, as illustrated in Fig. 1A, to insert a copy of the AU/U-
rich element of the human FOS gene into the mouse Edn1 gene
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just downstream of the stop codon, and therefore upstream of
the normal 3′ UTR of Edn1. [Inserting this AU/U-rich element
upstream of the 3′UTR of a test gene is known from our
previous work to lower gene expression levels to approximately
one-tenth (9).] To enable switching of the resulting L allele into
a high-expressing form (H) by Cre-loxP recombination, the L
allele also included loxP sites and the 3′UTR from a stable
mRNA: that of the adrenomedullin 2 gene.
L/+ mice were generated from embryonic stem cells having
the L allele, and H/+ mice were derived from them by breeding
with a mouse carrying a globally expressed Cre-recombinase
gene. By further breeding, mice were obtained that have the
desired combinations of the mutated (L and H) and WT (+)
alleles. Fig. 1B shows that the resulting mice have comparably
graded levels of Edn1 expression in the adrenal gland, heart,
kidney, liver, lung, and skin. (In this and subsequent figures, the
L/L level is shown as a black bar, L/+ level as a gray bar, WT
level as a white bar, and H/+ level as a red bar.) The average
mRNA levels relative to WT (100%) in the L/L, L/+, and H/+
mice were, respectively, ∼20%, ∼65%, and ∼350%WT. The L/L,
L/+, and H/+ mice had 31%, 65%, and 291% WT levels of the
mature peptide in their plasma (Fig. 1C). Thus, our study mice
have progressively graded levels of Edn1 expression ranging in all
tissues from ∼1/5 to ∼3.5 times normal, along with parallel
changes in plasma endothelin-1.
Survival and Baseline Characteristics of Endothelin-1 Hypo/
Hypermorphic Mice
Homozygosity for the H allele proved to be embryonically lethal;
no H/H embryos were found at 9.5 d post coitum. In contrast, the
L/L, L/+, WT, and H/+ mice were born and reached adulthood
in the expected Mendelian ratios and were fertile. The median
survival age of the L/L and L/+ mice was 560 and 632 d, re-
spectively (SI Appendix, Fig. S4). WT mice have a median sur-
vival of 841 d. The median survival age of the H/+mice was 876 d,
which is not different from WT.
The baseline characteristics of the L/L, L/+, WT, and H/+ mice
were largely indistinguishable (SI Appendix, Table S1). These
characteristics included body weight, kidney weight, heart weight,
and their ratios; plasma glucose; insulin; urea nitrogen; creatinine;
cholesterol; triglyceride; sodium; potassium; and chloride. How-
ever, the H/+ mice had significantly greater heart/body weights
than WT mice.
Systolic blood pressures and plasma volumes increased step-
wise and in parallel as Edn1 expression decreased (Fig. 1 D and
E). The pulse rate of the L/L mice, but not of the L/+ or H/+
mice, was significantly slower than that of WT mice (Fig. 1F).
Thus, progressive changes in the level of expression of the Edn1
gene do not affect the survival to adulthood and fertility of the
study mice but do cause progressive changes in their plasma
volumes and systolic blood pressures.
Dilated Cardiomyopathy in the Endothelin-1 L/L and L/+
Mice
Despite the normal survival of young adult endothelin-1 L/+ and
L/L mice, the left and right ventricles of their hearts at 12 wk
of age were markedly and progressively dilated as the expression
of Edn1 decreased (Fig. 2A). Remarkably, however, AZAN
(azocarmine + aniline blue) trichrome staining showed no overt
fibrosis in the dilated hearts. The hearts of the H/+ mice were
slightly larger than WT but appeared to be compact and mus-
cular, again without overt fibrosis. The changes in Edn1
expression caused changes in the ultrastructure of the car-
diomyocytes (Fig. 2B). Specifically, the L/L and L/+ car-
diomyocytes contained autophagosomes, which were more
prominent in the L/L mice than in the L /+ mice, which suggests
the occurrence of progressively increasing damage to and turn-
over of mitochondria as the expression of Edn1 decreases. This
suggestion is supported by our finding that the ratio of processed
to unprocessed microtubule-associated protein 1 light chain 3, an
index of autophagy (11), is more than normal in the hearts of the
L/+ and L/L mice and was less than normal in the H/+ mice (SI
Appendix, Fig. S5). In contrast, the ultrastructure of the H/+
cardiomyocytes differed little from WT, except for the presence
of intramyocellular lipid droplets. Previous studies have shown
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Fig. 1. Generation of hypo/hypermorphic mice for en-
dothelin-1. *P < 0.05; **P < 0.01; †P < 0.001; ††P < 0.0001;
‡P < 10−5 versus WT. (A) The gene-targeting strategy.
(a) The target locus, into which the exogenous 3′ UTR is
introduced by homologous recombination, is Edn1. (b) The
targeting vector contains the loxP sequence, the AU/U-rich
element (ARE) of human FOS 3′ UTR, the natural Edn1
3′ UTR, two copies of transcriptional insulators (cHS) of
chicken β-globin gene, the neomycin phosphotransferase
gene with the MC1 promoter (Neo), loxP (P), and the
3′UTR of the adrenomedullin 2 (Adm2) gene. The insulators
were inserted to minimize the transcriptional interference
between the Edn1 promoter and pMC1. (c) The resulting
locus after homologous recombination. The endothelin-1
expression is controlled by ARE, which destabilizes Edn1
mRNA and decreases endothelin-1 protein (L allele). Cod-
ing sequences of the Edn1 gene are shown as black col-
umns. (d) After Cre-loxP recombination, the floxed part is
removed and the endothelin-1 expression is controlled by
the 3′ UTR of Adm2, which stabilizes Edn1 mRNA and in-
creases endothelin-1 protein (H allele). (B) The mRNA lev-
els of Edn1 in different tissues in the four genotypes of
12-wk-old male mice. (C) Plasma concentrations of endo-
thelin-1 in the four genotypes. (D) Systolic blood pressure
(BP) on normal chow (0.26% [wt/wt] NaCl) determined
with a tail-cuff method. (E) Plasma volume normalized by
body weight (BW). (F) Heart rate on normal chow with a
tail-cuff method.
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with improvements in muscular function that result from training
(12). We conclude that reduced Edn1 expression results in mi-
tochondrial damage, whereas modestly increased Edn1 expres-
sion appears to have beneficial effects on metabolism.
The functional consequences of the different levels of Edn1
expression and quantification of the changes in thickness of the
heart walls were assessed by echocardiography (Fig. 2 C and D
and SI Appendix, Figs. S6 and S7). Cardiomyocyte fractional
shortening (FS) and ventricular ejection fractions (EF), clear
indicators of cardiac function, were reduced in both the L/+ and
L/L hearts but did not differ from WT in the H/+ mice (Fig. 2D).
As an assay of function, we carried out in vivo pressure volume
loop analysis with the study mice. The slope of end-systolic
pressure volume relationship, an index of myocardial contrac-
tility, showed a progressive decrease as Edn1 expression de-
creased below normal, indicating a decrease in myocardial
function, but was unaffected in the H/+ mice (Fig. 2E). In con-
trast, the slope of end-diastolic pressure volume relationship, an
index of ventricular stiffness, was more than twice normal in the
H/+ mice, whereas the L/L and L/+ mice had progressively less-
than-normal ventricular stiffness (Fig. 2F), thereby making their
hearts susceptible to dilatation. We conclude that cardiac func-
tion and stiffness deteriorates as Edn1 expression decreases,
whereas increased Edn1 expression has little effect on function
except that it makes the cardiomyocytes stiffer than normal.
We investigated the ventricular expression in the study mice of
several genes that are responsive to cardiovascular insults (Fig.
2G). Expression of the natriuretic peptide precursor genes (Nppa
and Nppc) were not significantly different among the four ge-
notypes; Nppb expression, increases of which are generally con-
sidered to be indicative of ventricular dysfunction, decreased
rather than increased as ventricular function deteriorated (SI
Appendix, Table S3). Expression of Myh7, the myosin beta heavy
chain gene, showed a remarkably strong gradation in expression
that paralleled that of Edn1. Expression of Myh6, the myosin
alpha heavy chain gene, was not affected by Edn1 expression.
MMPs play a key role in modulating fibrosis. Accordingly, we
determined expression of Mmp2 and Mmp9 in the study mice
(Fig. 2H). Mmp2 gene expression was not affected by Edn1 ex-
pression, but Mmp9 mRNA levels more than doubled in the
hearts of the L/+ mice, more than quadrupled in the L/L mice,
and were less than normal in the H/+ mice. Mmp9 protein levels
in the hearts changed in parallel with the mRNA levels (Fig. 3G).
We conclude that changes in levels of Edn1 cause marked pro-
gressive reciprocal changes in cardiac levels of Mmp9.
Effects on the Cardiovascular Abnormalities of Young Adult
L/L Mice of Tissue-Specifically Switching Endothelin-1
Expression from L to H
We next determined whether any of the cardiac abnormalities
caused by low expression of Edn1 can be reversed if expression is
switched to high in specific tissues. To do this, we used appro-
priate matings to generate L/L mice that also carried one of
three Cre transgenes that cause Edn1 expression to switch from
low to high after induction, as illustrated in Fig. 1A, c and d. The
first was a tamoxifen-inducible CAG promoter-driven transgene
(CAG-cre/Esr1), which is globally expressed after induction (13).
The second was a tamoxifen-inducible transgelin promoter-
driven transgene (Tagln-cre/ERT2), expressed in adult car-
diomyocytes and smooth muscle cells after tamoxifen induction
(14, 15). The third was a doxycycline-inducible troponin T
(Tnnt2) promoter-driven Cre transgene (Tnnt2-rtTA/TetO-cre),
which is expressed in cardiomyocytes after induction (16).
At 12 wk of age, all three transgene-carrying mice had the
increased blood pressure seen in L/L mice not carrying any
transgenes (SI Appendix, Fig. S8), and echocardiography showed
that they had already developed the abnormal cardiac function
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Fig. 2. Cardiac phenotype in male mice at age 12 wk.
*P < 0.05; **P < 0.01; †P < 0.001; ††P < 0.0001; ‡P < 10−5
versus WT. (A) Representative cross-sections of the heart
with Heidenhain’s AZAN trichrome staining. (B) Trans-
mission electron microscopy of the heart. Autophago-
somes (Au) are frequently found in the L/L and L/+ mice.
Lipid droplets (L) are prominent in the H/+ mice. (Scale
bar, 1 μm.) (C) Representative M-mode images of echo-
cardiography. (D) Echocardiographically determined sys-
tolic function of the left ventricle. (E) End-systolic pressure
volume relationship (ESPVR) determined by in vivo pressure-
volume loop analysis. (F) End-diastolic pressure volume re-
lationship (EDPVR) determined by the pressure-volume loop
analysis. (G) mRNA levels for natriuretic peptides and
myosin heavy chains in the heart. (H) mRNA levels for
Mmp2 and Mmp9 and Sod1 and Sod2 in the heart.











transgenes (SI Appendix, Figs. S9–12 A, C, and E). The mice
were then treated with tamoxifen or doxycycline to induce Cre
and cause switching of Edn1 expression from low to high. Four
weeks later, their cardiovascular status was reassessed.
The results show that switching from low to high had differing
effects, depending on the tissue in which the switching occurred.
Thus, in the mice having the tamoxifen-inducible ubiquitously
expressed CAG-cre transgene (orange bars in Fig. 3), switching
occurred in all tissues, and blood pressure was normalized (Fig.
3A). Echocardiography (SI Appendix, Fig. S12B) showed that
myocyte FS and ventricular EF were normalized (Fig. 3B) and
that the thinning of the interventricular septa and left ventricular
posterior walls that occurs in untreated L/L mice was resolved
(Fig. 3C). The left ventricular diameters also returned to normal
(orange bars in SI Appendix, Fig. S13). Thus, the cardiovascular
abnormalities already present in young adult mice with low
expression of Edn1 resolve if the expression is subsequently
switched to high throughout the body.
In mice having the tamoxifen-inducible Tagln-cre transgene,
switching from low to high in cardiomyocytes and smooth muscle
cells (brown bars in Fig. 3) did not correct blood pressure.
However, echocardiography (SI Appendix, Fig. S12D) showed
that myocyte FS and ventricular EF were restored (Fig. 3B),
although less well than with the ubiquitously expressed trans-
gene. The thinning of the interventricular septa and left ven-
tricular posterior walls was almost completely reversed (Fig. 3C).
The left ventricular diameters were partially corrected (brown
bars in SI Appendix, Fig. S13). Thus, although restoring expression
of Edn1 in cardiomyocytes and smooth muscle cells walls does
not normalize blood pressure of the L/L mice, it restores cardiac
function and substantially improves ventricular wall thickness.
The effects of switching from low to high only in cardiomyocytes
(green bars in Fig. 3) were indistinguishable from those observed
when switching also occurred in smooth muscle cells. We conclude
that the cardiac abnormalities observed in L/L mice are not a
result of low expression of Edn1 in smooth muscle cells.
Both global and cardiomyocyte-specific overexpression of
Edn1 restored the lifespan of the L/L mice to near normal (SI
Appendix, Fig. S14), suggesting that the shorter-than-normal
lifespan in the L/L mice is largely caused by heart problems.
Effects of Pharmacological Agents on the Cardiovascular
Abnormalities of Young Adult L/L Mice
Administration of amiloride, a diuretic inhibitor of the epithelial
sodium channel ENaC (yellow bars in Fig. 3), normalized the
blood pressure of the L/L mice (Fig. 3D) but incompletely cor-
rected myocyte FS and ventricular EF (Fig. 3E). The diuretic had
no effect on septal and ventricular wall thickness (Fig. 3F) or on
cardiac metalloproteinase Mmp9 expression (Fig. 3G). Left
ventricular dilatation was partially corrected (yellow bars in SI
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Fig. 3. Effects of postnatally global or tissue-specific overexpression of endothelin-1, pharmacological agents, and genetic deficiency of Mmp9 on the cardiac
phenotype in the L/L mice. *P < 0.05; **P < 0.01; †P < 0.001; ††P < 0.0001; ‡P < 10−5 versus L/L. (A) Systolic blood pressure (sBP) in the L/L mice with postnatally
global or tissue-specific overexpression of endothelin-1. CAG, L/L mice with CAG-cre; Tagln, L/L mice with Tagln-cre; Tnnt, L/L mice with Tnnt2-rtTA and TetO-cre.
(B) Systolic function of the left ventricle. (C) Ultrasonographically determined thicknesses of the left ventricle (LV) of the heart in mice with postnatally global or
tissue-specific overexpression of endothelin-1. TL, tibial length; IVSd and IVSs, interventricular septum thickness in diastole and systole; LVPWd and LVPWs, LV
posterior wall thickness in diastole and systole. (D) sBP in the L/L mice with pharmacologic agents and genetic deficiency of Mmp9. Ami, L/L mice with amiloride;
Temp, L/L mice with tempol; Mmp9, L/L mice with genetic deficiency of Mmp9. (E) Systolic function of the left ventricle. (F) Ultrasonographically determined
thicknesses of the LV of the heart in mice with pharmacologic agents and genetic deficiency of Mmp9. (G) Protein levels of Mmp9 in the heart. (H) Comparison of
Picrosirius Red birefringence. Tempol or Mmp9 deficiency significantly improved the birefringence, but amiloride did not, in the L/L mice. (I) Comparison of
2-dihydroethidium fluorescence in the heart. Amiloride and deficiency of Mmp9 did not significantly change the fluorescence in the L/L mice. (J) Collagen studied by
Picrosirius Red birefringence in the heart. (Scale bar, 20 μm.) (K) Superoxide studied by 2-dihydroethidium fluorescence in the heart. (Scale bar, 20 μm.)
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of the L/L mice are modest, suggesting they are probably the
indirect effects of reducing plasma volume.
Tempol, a stable free radical that acts as a superoxide dis-
mutase (SOD) mimetic (blue bars in Fig. 3), did not change blood
pressure in the L/L mice (Fig. 3D), although it modestly improved
myocyte FS and ventricular EF (Fig. 3E). However, in contrast to
amiloride, tempol substantially increased interventricular septal
thickness and left posterior ventricular wall thickness (Fig. 3F)
and partially corrected ventricular dilatation (blue bars in SI
Appendix, Fig. S15). In addition, tempol administration resolved
the abnormally high cardiac Mmp9 levels of L/L mice (Fig. 3G).
Effects of Genetic Deficiency of Mmp9 on the Cardiac
Function in the L/L Mice
In view of this observation that cardiac expression of Mmp9 is
affected by tempol and is markedly and progressively increased
in the L/+ and L/L mice (Fig. 2H), we asked whether genetic
absence of Mmp9 would have any effects on the cardiac abnor-
malities of the L/L mice. To do this, we used breeding to obtain
L/L mice that also have the Mmp9 gene knocked out (17). Lack
of Mmp9 (purple bars in Fig. 3) did not significantly affect blood
pressure (Fig. 3D). However, it significantly improved myocyte
FS and ventricular EF (Fig. 3E) and septal and ventricular wall
thickness (Fig. 3F) and removed ventricular dilatation (purple
bars in SI Appendix, Fig. S15) to the same extent as tempol. We
conclude that Mmp9 overproduction in the L/L mice is an im-
portant contributor to their ventricular dilatation.
Cardiac Collagen in the Study Mice
Although none of our study mice develop overt fibrosis, with or
without additional treatments or genetic modifications, the in-
volvement of Mmp9 in their cardiac abnormalities raises the
possibility that the amount of collagen in their hearts affects their
phenotypes. Accordingly, as measured in Fig. 3H and illustrated
in Fig. 3J, we determined the Picrosirius Red birefringence (a
measure of collagen type/amount) of the hearts of untreated L/L,
L/+, WT, and H/+ mice, as well as of L/L mice that had received
amiloride or tempol or genetically lacked Mmp9. The results are
clear: the birefringence in the L/L mice (black bar) and L/+ mice
(gray bar) was less than 50% that of WT mice (white bar),
whereas that in the H/+ mice (red bar) was increased to ∼125%.
The low birefringence of the L/L mice was not changed by
treatment with amiloride (yellow bar). In contrast, it was essentially
normalized by treatment with tempol (blue bar), or when the
production of Mmp9 was genetically knocked out (purple bar). We
conclude that the collagen content of the hearts of the mice with
even modestly less than normal Edn1 expression is considerably
reduced, whereas that of mice with higher expression is slightly
above normal; both tempol and absence of Mmp9 increase the
amount of collagen in the hearts of the L/L mice.
Cardiac Superoxide in the Study Mice
The marked improvements of the cardiac abnormalities in the
L/L mice caused by the administration of tempol emphasize the
importance of knowing the levels of superoxide in the study
mice. Accordingly, as measured in Fig. 3I and illustrated in Fig.
3K, we determined the fluorescence of 2-hydoxyethidium gen-
erated from dihydroethidium by superoxide (18, 19) in sections
of the hearts of our study mice. Fluorescence was higher in the
L/+ hearts (gray bar) than in the WT hearts (white bar), and
higher still in the hearts of the L/L mice (black bar). Fluores-
cence was lower in the H/+ hearts (red bar) than in WT. Ad-
ministration of tempol reduced superoxide levels in the L/L mice
to subnormal levels (blue bar). Fluorescence was not reduced
significantly in the hearts of the L/L mice treated with amiloride
(yellow bar) or with genetic absence of Mmp9 (purple bar).
Cardiac Expression of SODs in the Study Mice
The increased superoxide levels in the hearts of the L/L mice, and
the beneficial effects of tempol, raised the possibility that changes
in the expression of Edn1might be causing comparable changes in
the expression of the SODs. This was confirmed by our finding a
marked decrease in cardiac transcript and protein levels for Sod1
and Sod2 in the L/L mice (Fig. 2H and SI Appendix, Fig. S16). In
the reverse direction, a significant increase in Sod1 and Sod2 ex-
pression was found in the H/+mice. We conclude that endothelin-1
plays an important role in controlling the cardiac expression of
SODs, and thence the levels of superoxide in the heart.
Discussion
The molecular pathway underlying the increases in plasma vol-
umes and blood pressure that we find as Edn1 expression is
decreased from below normal in the L/+ and L/L mice is readily
identified. Thus, previous studies have shown that renal-
collecting duct-derived endothelin-1 acting via endothelin B (ETB)
receptors promotes Na+ excretion (20) and that stimulation of
both the endothelin A (ETA) and ETB receptor inhibits ENaC
activity (8, 21). We conclude that the increase in blood pressure
that occurs as endothelin-1 levels decrease is a result of an in-
crease in renal ENaC activity and the increase in plasma volume,
whereas the H/+ mice have lower than normal blood pressure
and plasma volume because of a decrease in renal ENaC activity.
Despite the increased plasma volumes in the L/L and L/+
mice, expression of two of the natriuretic peptide precursors,
Nppa and Nppc, were not significantly different among the four
genotypes, although Nppb expression tended to increase as Edn1
expression increased (SI Appendix, Table S3; P = 0.0116 for
significant slope). This result is in agreement with several pre-
vious findings. Thus, both ETA and ETA/ETB receptor antag-
onists decrease plasma atrial natriuretic peptide responses to
volume overload (22); the nonselective endothelin receptor an-
tagonist bosentan blocks the increase in Nppb mRNA levels
produced by pressure overload in the left atria (23), and anti-
endothelin-1 serum decreases the percentage of cells that secrete
C-type natriuretic peptides in human vascular endothelial cells
(24). Together, these studies suggest that below-normal expres-
sion of Edn1 probably suppresses the increased expression of
natriuretic peptides that is the normal response to volume ex-
pansion. Such a failure to properly induce natriuretic peptides
would likely aggravate the fluid retention caused by the renal
effects of decreased Edn1 expression and would contribute to the
increased plasma volumes of the L/L and L/+ hypomorphs.
Previous reports indicate that enhanced autophagy is associ-
ated with increased oxidative stress (25, 26). The decreased
transcript levels for Sod1 and Sod2 that we have observed in the
L/L and L/+ mice account for their increased levels in super-
oxide, which in turn contributes to their dilated cardiomyopathy.
The effect is probably direct, as it is reversed by the adminis-
tration of the stable free radical scavenger tempol. In support of
these inferences, mice lacking SOD2 exhibit severe dilated car-
diomyopathy with mitochondrial damage in their cardiomyocyte
(27). In addition, a recent proteomic screening study has dem-
onstrated that SOD2 protein levels are increased in transgenic
mice expressing increased amounts of endothelin-1 (28).
Our L gene was designed to enable Cre recombinase-inducible
switching of expression from L to H at will in a tissue-specific
manner. With its use, we found that dilated cardiomyopathy al-
ready established in young adult L/L mice was almost completely
reversed by switching expression from low to high throughout the
body. Switching in cardiomyocytes only was equally effective. These
findings are important in establishing that dilated cardiomyopathy
caused by less-than-normal expression of Edn1 is reversible.
Administration of the diuretic amiloride corrected the blood
pressure and partially removed the ventricular dilatation that











occurs in the L/L mice but did not correct the increased Mmp9
levels. The SOD mimetic tempol, in contrast, failed to correct
the increased blood pressure of the L/L mice but abolished the
increased superoxide, which damages cardiomyocytes. It also
reduced the increased level of the metalloproteinase Mmp9,
which degrades ventricular collagen. Thus, our results suggest
that pharmaceutical interventions affecting either superoxide
and/or MMP9 levels should be considered for reversing the
cardiovascular problems caused by decreased Edn1 expression.
The interplay between these two apparently unrelated factors
has been recently described in relation to cardiac rupture after
myocardial infarction (29) and neurodegeneration in amyo-
trophic lateral sclerosis (30). At what level and how the two
systems interact remains to be determined.
The increased blood pressure in our L/L and L/+ mice prob-
ably contributes to their developing well-established dilatation by
age 12 wk without the need to stress them, whereas mice with a
cardiac-specific knock-out of the Edn1 gene only developed di-
latation at a much older age (≥8 mo) or after aortic banding to
increase their intraventricular blood pressure (6).
In the opposite direction, transgenic mice with ∼15 times normal
cardiomyocyte-specific expression of endothelin-1 peptide develop
marked cardiac hypertrophy with dilatation and contractile dys-
function, and they die of congestive heart failure between 5 and 11 wk
after the transgene induction (7), whereas our H/+ mice globally
expressing ∼3.5 times normal levels of Edn1 have only slightly hy-
pertrophic hearts with good function. Thus, threefold higher than
normal Edn1 expression has small possibly even beneficial effects
on cardiac function, but 15-fold higher expression is harmful.
An important question our study answers is whether there are
any cardiac consequences of modest decreases in Edn1 expression,
such as might occur in humans either clinically or as a result of
genetic differences. The answer is clear: even the 35% decrease in
Edn1 expression we see in the L/+ mice causes dilated cardio-
myopathy and severe cardiac dysfunction. Similar detrimental ef-
fects can be expected in patients treated with endothelin receptor
antagonists. Indeed, it has been reported that adverse effects in-
cluding fluid retention, congestive heart failure, and death resul-
ted in discontinuation of trial medication of an endothelin ETA
receptor antagonist (31).
In summary, we find that mice with progressively decreased
expression of Edn1, the gene coding for endothelin-1, have in-
creased plasma volumes and hypertension and spontaneously de-
velop severe dilated cardiomyopathy together with increased
superoxide levels and increased expression of matrix metal-
loproteinase Mmp9 in their hearts. The cardiovascular abnormal-
ities already established in young adult hypomorphs were almost
completely reversed by switching Edn1expression from low to high
throughout the body or in cardiomyocytes only. The increased
plasma volumes and blood pressure of the hypomorphs were
normalized by an ENaC antagonist, although superoxide levels and
Mmp9 expression remained high and the impaired cardiac function
was only partially ameliorated. In contrast, a SOD mimetic de-
creased both superoxide levels and the expression of Mmp9 in the
hypomorphs and greatly improved the condition of their hearts,
although it did not change blood pressure. Nevertheless, these
experiments show that the cardiovascular abnormalities caused by
less-than-normal Edn1 expression are amenable to correction by
pharmacologic treatment. Genetic deficiency of Mmp9 also miti-
gated the dilated cardiomyopathy in the hypomorphs but did not
change the superoxide levels. Together, our results show that
endothelin-1 is critical for maintaining normal contractile func-
tion, for controlling superoxide and Mmp9 levels, and for ensuring
that the myocardium has sufficient collagen to prevent over-
stretching during systole. Even a modest (∼35%) decrease in Edn1
expression is sufficient to cause severe cardiovascular dysfunction.
ACKNOWLEDGMENTS. We thank Dr. Firouz Daneshgari (Case Western
Reserve University) for his kind donation of mice having Tagln-cre/ERT2
and Ms. Sandee English for secretary assistance. This work was supported by
NIH Grants HL49277, HL70523, HL71266, and DK34987 and by Career De-
velopment Award 2006-102 from the Juvenile Diabetes Research Foundation.
1. Hiroe M, et al. (1991) Plasma endothelin-1 levels in idiopathic dilated cardiomyopa-
thy. Am J Cardiol 68(10):1114–1115.
2. Plumpton C, Ashby MJ, Kuc RE, O’Reilly G, Davenport AP (1996) Expression of en-
dothelin peptides and mRNA in the human heart. Clin Sci (Lond) 90(1):37–46.
3. Telgmann R, et al. (2007) The G-231A polymorphism in the endothelin-A receptor
gene is associated with lower aortic pressure in patients with dilated cardiomyopathy.
Am J Hypertens 20(1):32–37.
4. Herrmann S, et al. (2001) A polymorphism in the endothelin-A receptor gene predicts
survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 22(20):1948–1953.
5. Kurihara Y, et al. (1994) Elevated blood pressure and craniofacial abnormalities in
mice deficient in endothelin-1. Nature 368(6473):703–710.
6. Zhao XS, Pan W, Bekeredjian R, Shohet RV (2006) Endogenous endothelin-1 is re-
quired for cardiomyocyte survival in vivo. Circulation 114(8):830–837.
7. Yang LL, et al. (2004) Conditional cardiac overexpression of endothelin-1 induces
inflammation and dilated cardiomyopathy in mice. Circulation 109(2):255–261.
8. Lynch IJ, Welch AK, Kohan DE, Cain BD, Wingo CS (2013) Endothelin-1 inhibits sodium
reabsorption by ET(A) and ET(B) receptors in the mouse cortical collecting duct. Am J
Physiol Renal Physiol 305(4):F568–F573.
9. Kakoki M, et al. (2004) Altering the expression in mice of genes by modifying their 3′
regions. Dev Cell 6(4):597–606.
10. Mawji IA, Robb GB, Tai SC, Marsden PA (2004) Role of the 3′-untranslated region of
human endothelin-1 in vascular endothelial cells. Contribution to transcript lability
and the cellular heat shock response. J Biol Chem 279(10):8655–8667.
11. Kabeya Y, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in
autophagosome membranes after processing. EMBO J 19(21):5720–5728.
12. Tarnopolsky MA, et al. (2007) Influence of endurance exercise training and sex on intra-
myocellular lipid and mitochondrial ultrastructure, substrate use, and mitochondrial en-
zyme activity. Am J Physiol Regul Integr Comp Physiol 292(3):R1271–R1278.
13. Hayashi S, McMahon AP (2002) Efficient recombination in diverse tissues by a
tamoxifen-inducible form of Cre: A tool for temporally regulated gene activation/
inactivation in the mouse. Dev Biol 244(2):305–318.
14. Kühbandner S, et al. (2000) Temporally controlled somatic mutagenesis in smooth
muscle. Genesis 28(1):15–22.
15. Li L, Miano JM, Mercer B, Olson EN (1996) Expression of the SM22alpha promoter in
transgenic mice provides evidence for distinct transcriptional regulatory programs in
vascular and visceral smooth muscle cells. J Cell Biol 132(5):849–859.
16. Wu B, et al. (2010) Inducible cardiomyocyte-specific gene disruption directed by the
rat Tnnt2 promoter in the mouse. Genesis 48(1):63–72.
17. Vu TH, et al. (1998) MMP-9/gelatinase B is a key regulator of growth plate angio-
genesis and apoptosis of hypertrophic chondrocytes. Cell 93(3):411–422.
18. Robinson KM, et al. (2006) Selective fluorescent imaging of superoxide in vivo using
ethidium-based probes. Proc Natl Acad Sci USA 103(41):15038–15043.
19. Dugan LL, et al. (2013) AMPK dysregulation promotes diabetes-related reduction of
superoxide and mitochondrial function. J Clin Invest 123(11):4888–4899.
20. Ge Y, et al. (2006) Collecting duct-specific knockout of the endothelin B receptor causes
hypertension and sodium retention. Am J Physiol Renal Physiol 291(6):F1274–F1280.
21. Bugaj V, et al. (2008) Regulation of the epithelial Na+ channel by endothelin-1 in rat
collecting duct. Am J Physiol Renal Physiol 295(4):F1063–F1070.
22. Leskinen H, Vuolteenaho O, Ruskoaho H (1997) Combined inhibition of endothelin
and angiotensin II receptors blocks volume load-induced cardiac hormone release.
Circ Res 80(1):114–123.
23. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H (1997) Endothelin-1 is involved in
stretch-induced early activation of B-type natriuretic peptide gene expression in atrial
but not in ventricular myocytes: Acute effects of mixed ET(A)/ET(B) and AT1 receptor
antagonists in vivo and in vitro. Circulation 96(9):3053–3062.
24. Evans JJ, Youssef AH, Yandle TG, Lewis LK, Nicholls MG (2002) Effects of endothelin-1
on release of adrenomedullin and C-type natriuretic peptide from individual human
vascular endothelial cells. J Endocrinol 175(1):225–232.
25. Brunk UT, Jones CB, Sohal RS (1992) A novel hypothesis of lipofuscinogenesis and
cellular aging based on interactions between oxidative stress and autophagocytosis.
Mutat Res 275(3-6):395–403.
26. Marambio P, et al. (2010) Glucose deprivation causes oxidative stress and stimulates
aggresome formation and autophagy in cultured cardiac myocytes. Biochim Biophys
Acta 1802(6):509–518.
27. Li Y, et al. (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice
lacking manganese superoxide dismutase. Nat Genet 11(4):376–381.
28. Vignon-Zellweger N, et al. (2014) Endothelin-1 overexpression and endothelial nitric
oxide synthase knock-out induce different pathological responses in the heart of
male and female mice. Life Sci 118(2):219–225.
29. He BJ, et al. (2011) Oxidation of CaMKII determines the cardiotoxic effects of aldo-
sterone. Nat Med 17(12):1610–1618.
30. Kaplan A, et al. (2014) Neuronal matrix metalloproteinase-9 is a determinant of se-
lective neurodegeneration. Neuron 81(2):333–348.
31. Mann JF, et al.; ASCEND Study Group (2010) Avosentan for overt diabetic nephrop-
athy. J Am Soc Nephrol 21(3):527–535.
5146 | www.pnas.org/cgi/doi/10.1073/pnas.1504557112 Hathaway et al.
